ClinicalTrials.gg
CompletedNCT00717561Updated Nov 4, 2014

A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia

A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin in Pneumonia, sponsored by Bayer. Completed at 23 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-04.

Primary conditionCommunity-Acquired PneumoniaRegistry: PneumoniaReclassifiedWhy we changed it
Registry
Pneumonia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Community-Acquired Pneumonia
Why
  1. The study's title name Community-Acquired Pneumonia, a narrower term within Pneumonia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Community-Acquired Pneumonia with a site in Italy — 6 open to participants now, 6 under way, 2 of them phase 3. Community-Acquired Pneumonia · Italy.

Started
2008
the only one that year
Phase 3
4 of 17
2 open now
Registered
2nd of 17
by date
Lead sponsor
1 of 17
Bayer

Among the 17 studies in Community-Acquired Pneumonia with a site in Italy, this one is the only one that started in 2008, is one of 4 in phase 3, and was the 2nd registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

6 of the 17 studies in Community-Acquired Pneumonia with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Community-Acquired Pneumonia with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone + intravenous azithromycin followed by oral amoxicilline/clavulanate and oral clarithromycin in the treatment of community-acquired pneumonia.

03

Conditions studied

  • Pneumonia

Browse trials for

Keywords

  • CAP
  • Community-acquired pneumonia
04

In context

Community-Acquired Pneumonia Reclassified

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

This study's enrollment of 60 is below the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Community-Acquired Pneumonia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized non-ICU patients (age, >= 18 years)
  • Clinical signs and symptoms of CAP, with PSI score IV or V
  • Radiologically confirmed evidence of a new and/or progressive infiltrate(s)
  • Requirement for initial parenteral therapy
  • At least 2 of the following conditions:

    • Productive or non productive cough with or without purulent or mucosus or mucopurulent sputum
    • Dyspnea and/or tachypnea (respiratory rate of > 20 breaths/min)
    • Rigors and/or chills
    • Pleuritic chest pain
    • Auscultatory findings of rales and/or crackles on pulmonary examination and/or evidence of pulmonary consolidation
    • Fever (an oral temperature of >= 38 °C, a rectal temperature of >= 39 °C, or a tympanic temperature of >= 38.5 °C) or hypothermia (rectal or core temperature of \< 35 °C), and a WBC count of >= 10,000 cells/mm3 or >= 15% immature neutrophils bands; regardless of peripheral WBC count) or leukopenia (total WBC count of \< 4500 cells/mm3)
  • Written

Exclusion criteria

Exclusion Criteria:

  • PSI Class I-III and V with need for ICU admission
  • Hospitalization for > 48 hours before developing pneumonia, or discharge from hospital \< 30 days prior. Note: patients currently residing in residential long-term facilities can be enrolled in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

  • Active comparator
    Arm 2

    Drug: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin

Interventions

  • IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours

  • DrugCeftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin

    Drug pages: Ceftriaxone · Azithromycin · Amoxicillin · Clavulanic Acid · Clarithromycin

    IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.

07

What researchers measure

Primary outcomes

  1. Clinical response 20 days after completion of study treatment (Test-of-Cure visit)

    Time frame: 20 days after last dose of study drug (TOC Visit)

Secondary outcomes

  1. Clinical and bacteriological response on the day of switch from IV to oral therapy

    Time frame: Day of switch from IV to oral therapy

  2. Clinical and bacteriological response on treatment Day 3-5 (if the day of switch is different from Day 3, 4 or 5)

    Time frame: Day 3-5

  3. Bacteriological response at TOC

    Time frame: 20 days after last dose of study drug

  4. Clinical and bacteriological response at the end of treatment

    Time frame: Day 7-14 after first dose of study drug

  5. Mortality attributable to pneumonia at the Test-of-Cure visit

    Time frame: 20 days after last dose of study drug

08

Study locations

23 sites
  • Lungro, Cosenza 87010, Italy
  • San Cesario, Lecce 73016, Italy
  • Fossombrone, Pesaro e Urbino 61034, Italy
  • Pregiato di Cava dei Tirreni, Salerno 84013, Italy
  • Vittorio Veneto, Treviso 31029, Italy
  • Ascoli Piceno, 63100, Italy
  • Benevento, 82100, Italy
  • Brescia, 25123, Italy
  • Catania, 95122, Italy
  • Chieti, 66100, Italy
  • Foggia, 71100, Italy
  • Lucca, 55100, Italy
  • Macerata, 62100, Italy
  • Messina, 98125, Italy
  • Milano, 20142, Italy
  • Milano, 20157, Italy
  • Palermo, 90146, Italy
  • Roma, 00135, Italy
  • Roma, 00168, Italy
  • Roma, 00184, Italy
  • Sassari, 07100, Italy
  • Torino, 10154, Italy
  • Udine, 33100, Italy
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of May 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2008
First posted
Jul 17, 2008
Start
Feb 2008
Primary completionActual
May 2009
CompletionActual
Jun 2009
Last update
Nov 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00717561
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 17, 2008
Start date
Feb 2008
Primary completion
May 2009
Completion
Jun 2009
Last update
Nov 4, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion